Takeda Pharmaceutical Company Limited

Cardurion Pharmaceuticals, LLC

Scohia Pharma, Inc.

Yoichi Nishikawa

Keiko Kakegawa

Minoru Sasaki

Zenichi Ikeda

Fumiaki Kikuchi

Takeshi Yamasaki

Junya Shirai

Xiaolun Wang

Tomohiro Okawa

Nicholas Scorah

John S Tyhonas

Minoru Yoshida

Terufumi Takagi

Mark Sabat

Phong H Vu

Shizuo Kasai

Yasufumi Miyamoto

Joanne Miura

Akito Shibuya

Tohru Yamashita

Rei Okamoto

Zenyu Shiokawa

Yuta Tanaka

Haixia Wang

Hideki Hirose

Yoshito Terao

Nobuyuki Matsunaga

Lily Kwok

Asato Kina

Takafumi Yukawa

Mallareddy Komandla

Takeshi Yoshikawa

Takashi Nakahata

Hiroki Takahagi

Paul Tanis

Kazuaki Takami

Shigekazu Sasaki

Koichiro Fukuda

Yoshihiro Banno

Masahiro Kamaura

Kazuhiko Mori

Yusuke Minagawa

Ayumu Watanabe

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Substituted amines for treating cardiac diseases

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. 

Heterocyclic compound

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (I) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification].

Fused heterocyclic compound

The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification]. 

Condensed heterocyclic compound

A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: 

Tetrahydronaphthyridine somatostatin receptor 5 antagonists

A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein,or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.

A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein,or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent the prophylaxis or treatment of diabetes mellitus are provided.

Growing community of inventors

Kanagawa, Japan

Yoichi Nishikawa